Published in BMC Microbiol on December 21, 2003
Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis (2009) 0.95
Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog (2013) 0.93
Fatal giant cell myocarditis in a patient with multiple autoimmune disorders. BMJ Case Rep (2009) 0.77
The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier. Case Reports Immunol (2012) 0.75
From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation (1999) 2.34
Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid. Cell (1996) 2.31
Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med (2000) 2.23
The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis. J Virol (1995) 1.83
Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol (1991) 1.67
Clinical and experimental aspects of viral myocarditis. Clin Microbiol Rev (1989) 1.41
Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol (1997) 1.32
Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells. J Immunol (1999) 1.30
Chronic enteroviral meningoencephalitis in agammaglobulinemia: case report and literature review. J Clin Immunol (1992) 1.26
Pathogenesis of murine enterovirus myocarditis: virus dissemination and immune cell targets. J Virol (1996) 1.22
Meta-analysis of the association of enteroviruses with human heart disease. Heart (1997) 1.20
Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol (1993) 1.18
The use of mycophenolate mofetil in transplant recipients. Immunopharmacology (2000) 1.13
Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J Immunol (1991) 1.12
Direct interactions of coxsackievirus B3 with immune cells in the splenic compartment of mice susceptible or resistant to myocarditis. J Virol (1996) 1.11
Viral damage or 'molecular mimicry'-placing the blame in myocarditis. Nat Med (2000) 1.11
The immune system in viral myocarditis: maintaining the balance. Circ Res (1999) 1.05
Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis. J Immunol (1995) 1.05
The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. Eur Heart J (1995) 1.03
Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J Gen Virol (2002) 1.03
The role of B lymphocytes in coxsackievirus B3 infection. Am J Pathol (1999) 1.02
Effects of prednisolone on acute viral myocarditis in mice. J Am Coll Cardiol (1986) 1.02
Incidence of myocarditis. A 10-year autopsy study from Malmö, Sweden. Arch Pathol Lab Med (1991) 0.96
A case of protracted coxsackie virus meningoencephalitis in a marginally immunodeficient child treated successfully with intravenous immunoglobulin. J Neurol Sci (1995) 0.95
Antibody-mediated immune enhancement in coxsackievirus B3 myocarditis. J Mol Cell Cardiol (2002) 0.94
The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob Agents Chemother (2004) 0.92
Anti-Coxsackievirus B3 neutralizing antibodies with pathological potential. Eur Heart J (1991) 0.91
Coxsackie B3 virus encephalitis in a patient with agammaglobulinaemia. Eur J Pediatr (1989) 0.91
The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin Immunopathol (1993) 0.90
Adenoviruses and enteroviruses as pathogens in myocarditis and dilated cardiomyopathy. Acta Cardiol (1999) 0.89
T cell-mediated immune response enhances the severity of myocarditis in secondary cardiotropic virus infection in mice. Basic Res Cardiol (2001) 0.85
Treatment of experimental murine Coxsackie B3 myocarditis. Eur Heart J (1991) 0.83
The effects of FK-506, a novel and potent immunosuppressant, upon murine Coxsackievirus B3 myocarditis. J Pharmacol Exp Ther (1992) 0.82
New trends in immunosuppression. Drugs Today (Barc) (2000) 0.81
Immunosuppression with high doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus B3 myocarditis. Circulation (1990) 0.80
Coxsackie B virus infection in idiopathic dilated cardiomyopathy: clinical and pharmacological implications. BioDrugs (2001) 0.80
Antiviral treatment with WIN 54 954 reduces mortality in murine coxsackievirus B3 myocarditis. Circulation (1996) 0.79
Impact of mycophenolate mofetil on recurrent rejection in kidney transplant patients. Clin Transplant (2001) 0.79
Enteroviral RNA in dilated cardiomyopathy. Eur Heart J (1994) 0.79
Role of antiviral antibodies in resistance against coxsackievirus B3 infection: interaction between preexisting antibodies and an interferon inducer. Infect Immun (1982) 0.78
Inhibition of coxsackie B3 virus induced myocarditis in mice by 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile. J Med Virol (2004) 0.78
Mycophenolate mofetil: suggested guidelines for use in kidney transplantation. BioDrugs (2001) 0.77
Viral myocarditis: immunopathogenesis and the effect of immunosuppressive treatment in a murine model. Jpn Circ J (1989) 0.76
Heart transplantation in the young and elderly. Heart Fail Rev (2001) 0.76
Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med (2002) 5.50
HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem (2002) 4.91
LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem (2003) 3.97
Synthesis and biological activity of 4-thiazolidinones, thiosemicarbazides derived from diflunisal hydrazide. Eur J Med Chem (2006) 3.79
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett (2002) 3.56
An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol (2005) 3.36
Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development. Hepatology (2009) 3.16
Synthesis and antiviral activity evaluation of some new 6-substituted 3-(1-adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles. Farmaco (2002) 2.47
Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 2.45
Noninvasive and invasive pulmonary function in mouse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol (2009) 2.26
The sequential changes in myocardial thickness and thickening which occur during acute transmural infarction, infarct reperfusion and the resultant expression of reperfusion injury. Eur Heart J (2004) 2.25
Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev (2005) 2.24
Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis (2002) 2.22
Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3⁺ regulatory T cells. Nat Immunol (2013) 2.21
Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. J Antimicrob Chemother (2005) 2.14
Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation (2009) 2.05
Design, synthesis and cytotoxic properties of novel 1-[4-(2-alkylaminoethoxy)phenylcarbonyl]-3,5-bis(arylidene)-4-piperidones and related compounds. Eur J Med Chem (2006) 2.04
Synthesis and anti-hIV activity of 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole structurally-related 1,2-substituted benzimidazoles. Farmaco (2002) 2.04
Interferon-gamma: a historical perspective. Cytokine Growth Factor Rev (2009) 2.03
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology (2006) 1.99
Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties. Bioorg Med Chem Lett (2003) 1.97
Discrepancy between the in vitro and in vivo effects of murine mesenchymal stem cells on T-cell proliferation and collagen-induced arthritis. Arthritis Res Ther (2010) 1.95
The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol (2005) 1.91
Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res (2009) 1.87
A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat Genet (2011) 1.78
Influence of 2-substituent on the activity of imidazo[1,2-a] pyridine derivatives against human cytomegalovirus. Bioorg Med Chem (2002) 1.77
Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems. J Med Chem (2007) 1.76
The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (2007) 1.76
Differential effects of progenitor cell populations on left ventricular remodeling and myocardial neovascularization after myocardial infarction. J Am Coll Cardiol (2010) 1.70
Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum (2009) 1.70
Design, synthesis, and evaluation of 2-aryl-3-heteroaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Bioorg Med Chem (2006) 1.68
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem (2009) 1.64
In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol (2003) 1.63
Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J Virol (2003) 1.61
Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-gamma. Arthritis Res Ther (2005) 1.60
Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob Agents Chemother (2004) 1.60
Synthesis of some novel heterocyclic compounds derived from diflunisal hydrazide as potential anti-infective and anti-inflammatory agents. Eur J Med Chem (2007) 1.60
Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem (2010) 1.59
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One (2010) 1.59
Synthesis, antibacterial, antifungal and antiviral activity evaluation of some new bis-Schiff bases of isatin and their derivatives. Molecules (2007) 1.55
CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS (2004) 1.55
Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol (2003) 1.54
Clinical features and treatment of adenovirus infections. Rev Med Virol (2008) 1.53
Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum Gene Ther (2003) 1.53
How interferon-gamma keeps autoimmune diseases in check. Trends Immunol (2008) 1.53
A synthetic HIV-1 Rev inhibitor interfering with the CRM1-mediated nuclear export. Proc Natl Acad Sci U S A (2002) 1.53
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Design, synthesis, structure-activity relationships, and molecular modeling studies of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. J Med Chem (2002) 1.51
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature (2005) 1.51
Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics. J Antimicrob Chemother (2011) 1.51
Selective inhibitors of picornavirus replication. Med Res Rev (2008) 1.50
A case for developing antiviral drugs against polio. Antiviral Res (2008) 1.50
Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent. Antimicrob Agents Chemother (2008) 1.46
In vitro selection and characterization of HCV replicons resistant to multiple non-nucleoside polymerase inhibitors. J Hepatol (2011) 1.45
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator. Blood (2008) 1.45
Antiviral therapy: quo vadis? Future Med Chem (2010) 1.44
Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents. J Invasive Cardiol (2002) 1.44
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun (2004) 1.42
Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy]pyrimidine and related compounds. Bioorg Med Chem (2004) 1.41
Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation (2005) 1.40
Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol (2011) 1.37
Hydantoin derivatives of L- and D-amino acids: synthesis and evaluation of their antiviral and antitumoral activity. Molecules (2006) 1.36
The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-α receptor. Nat Immunol (2011) 1.36
Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur J Med Chem (2008) 1.36
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Design, synthesis, and biological evaluation of hybrid molecules containing alpha-methylene-gamma-butyrolactones and polypyrrole minor groove binders. J Med Chem (2004) 1.35
External aortic root support: a histological and mechanical study in sheep. Interact Cardiovasc Thorac Surg (2013) 1.35
Synthesis of new benzimidazole-coumarin conjugates as anti-hepatitis C virus agents. Antiviral Res (2007) 1.33
Acute toxicity and prothrombotic effects of quantum dots: impact of surface charge. Environ Health Perspect (2008) 1.32
Molecular strategies to inhibit the replication of RNA viruses. Antiviral Res (2008) 1.31
Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc (2008) 1.29
Anti-influenza virus agents: synthesis and mode of action. Med Res Rev (2008) 1.28
Zinc(II) complexes of constrained antiviral macrocycles. Dalton Trans (2012) 1.28
5-Substituted-2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]pyrimidines-acyclic nucleoside phosphonate analogues with antiviral activity. J Med Chem (2003) 1.28
Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS (2004) 1.28
3,5-Bis(benzylidene)-4-oxo-1-phosphonopiperidines and related diethyl esters: Potent cytotoxins with multi-drug-resistance reverting properties. ChemMedChem (2009) 1.27
Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication. Cell Res (2012) 1.27
Design and synthesis of bioactive adamantane spiro heterocycles. Bioorg Med Chem Lett (2007) 1.27
Synthesis and antiviral evaluation of benzimidazoles, quinoxalines and indoles from dehydroabietic acid. Bioorg Med Chem (2004) 1.26
Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother (2007) 1.26
The regulation of HIV-1 transcription: molecular targets for chemotherapeutic intervention. Med Res Rev (2006) 1.24
Deoxythreosyl phosphonate nucleosides as selective anti-HIV agents. J Am Chem Soc (2005) 1.24
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2011) 1.23
Cytotoxic 5-aryl-1-(4-nitrophenyl)-3-oxo-1,4-pentadienes mounted on alicyclic scaffolds. Eur J Med Chem (2006) 1.21
Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J Virol (2006) 1.21
The cytotoxic properties and preferential toxicity to tumour cells displayed by some 2,4-bis(benzylidene)-8-methyl-8-azabicyclo[3.2.1] octan-3-ones and 3,5-bis(benzylidene)-1-methyl-4-piperidones. Eur J Med Chem (2008) 1.20
CXCR3 determines strain susceptibility to murine cerebral malaria by mediating T lymphocyte migration toward IFN-gamma-induced chemokines. Eur J Immunol (2008) 1.20
Synthesis and antiviral/antiproliferative activity of some N-sulphonylbenzimidazoles. Bioorg Med Chem Lett (2002) 1.19
Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents. Eur J Med Chem (2007) 1.19
Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother (2008) 1.18